These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38445964)

  • 1. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
    Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
    Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
    Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
    J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
    Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C; MacDonald T; Mueller S; Faison SL; Allen JE; Naderer OJ; Ramage SC; Tarapore RS; McGovern SL; Khatua S; Zaky W; Gardner SL
    Neuro Oncol; 2024 May; 26(Supplement_2):S155-S164. PubMed ID: 38400780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma.
    Akinduro OO; Garcia DP; Higgins DMO; Vivas-Buitrago T; Jentoft M; Solomon DA; Daniels DJ; Pennington Z; Sherman WJ; Delgardo M; Bydon M; Kalani MA; Zanazzi G; Tsankova N; Bendok BR; McCormick PC; Sciubba DM; Lo SL; Clarke JL; Abode-Iyamah K; Quiñones-Hinojosa A
    J Neurosurg Spine; 2021 Aug; 35(6):834-843. PubMed ID: 34416733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
    Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
    J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
    van den Bent M; Saratsis AM; Geurts M; Franceschi E
    Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
    Kleinschmidt-DeMasters BK; Mulcahy Levy JM
    Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adult case of diffuse midline glioma with H3 K27M mutation.
    Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
    Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.
    Yi S; Choi S; Shin DA; Kim DS; Choi J; Ha Y; Kim KN; Suh CO; Chang JH; Kim SH; Yoon DH
    Neurosurgery; 2019 May; 84(5):1072-1081. PubMed ID: 29718432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.